The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Fruzaqla was licensed by Takeda from China's Hutchmed for $400 million upfront in 2023 and has also been approved in the US ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

The CGM is based on magnetohydrodynamic (MHD) technology, which non-invasively samples interstitial fluid, the body fluid ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

The UK’s regulator, the MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...